Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial
| Autor: | Dent, S., Cortés, J., Im, Y.-H., Diéras, V., Harbeck, N., Krop, I.E., Wilson, T.R., Cui, N., Schimmoller, F., Hsu, J.Y., He, J., De Laurentiis, M., Sousa, S., Drullinsky, P., Jacot, W. |
|---|---|
| Zdroj: | In Annals of Oncology February 2021 32(2):197-207 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|